Incidence, Histopathological Features and Differential Diagnosis of Cutaneous Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation

Ugur Payam Hacisalihoglu, Davut Sahin

Department of Pathology, Istanbul Yeni Yuzuil University Faculty of Medicine, Gaziosmanpasa Hospital, Istanbul, Turkey
Department of Pathology, Acibadem Health Group, Istanbul, Turkey

Abstract

Objectives: Hematopoietic stem cell transplantation by allogeneic bone marrow transplantation is a method used in the treatment of various genetic, immunological disorders, hematologic and solid organ malignancies. Graft versus Host Disease is one of the major and fatal complications of allogeneic bone marrow transplantation. It is a systemic disease affecting five main areas: skin, gastrointestinal tract, liver, lung and hematopoietic system. Diagnosis of cutaneous Graft versus Host Disease is made by the correlation between clinical and histopathological findings of the patient. The present study aims to investigate the incidence of cutaneous graft versus Host Disease in allogeneic bone marrow transplantation patients in our center, to discuss the histopathological features and differential diagnosis of cutaneous graft versus Host Disease in the light of the literature.

Methods: The pathology slides of allogeneic bone marrow transplantation patients who were diagnosed as graft versus Host Disease in our pathology department between January 2015 and January 2019 were re-evaluated. Epidermal and dermal histomorphological findings of the disease were classified; the patients’ clinical and demographic information was obtained from the files. The incidence of cutaneous Graft versus Host Disease was calculated.

Results: In our center, between January 2015 and January 2019, 273 pediatric and 100 adult patients underwent allogeneic and 181 autologous bone marrow transplantation. Twenty-three patients who underwent allogeneic bone marrow transplantation had cutaneous Graft versus Host Disease whereas and 21 patients had gastrointestinal Graft versus Host Disease. The incidence of cutaneous and gastrointestinal Graft versus Host Disease was 16.1% whereas the incidence of cutaneous Graft versus Host Disease was 8.42%. The most common clinical differential diagnosis of cutaneous Graft versus Host Disease was drug reaction (74%). The most common epidermal histomorphologic finding in our cases was keratinocyte necrosis (87%). In our cases, the most common epidermal histomorphologic finding was keratinocyte necrosis (87%). This was followed by vacuolar degeneration in basal keratinocytes (63%), acanthosis and spongiosis (61%), respectively. The most common finding in the dermis was pigment incontinence (59%). Of the patients with Graft versus Host Disease, 56% had transplantation from unrelated donors, whereas 44% of them had transplantation from their relatives.

Conclusion: Cutaneous Graft versus Host Disease is a common complication of allogeneic hematopoietic stem cell transplantation. It is associated with high mortality rates and has a significant negative impact on the patient’s quality of life. Dermatological early recognition of the disease; histopathological evaluation and verification with differential diagnosis plays a key role in preventing patient morbidity and mortality.

Keywords: Differential diagnosis, histopathologic, GvHD, Graft versus Host Disease, incidence.

Please cite this article as “Hacisalihoglu UP, Sahin D. Incidence, Histopathological Features and Differential Diagnosis of Cutaneous Graft Versus Host Disease in Allogeneic Bone Marrow Transplantation. Med Bull Sisli Etfal Hosp 2021;55(1):68–75”.
Graft versus Host Disease (GvHD) is a complication that is one of the most important causes of morbidity and mortality in allogeneic bone marrow transplantation (BMT) recipients. The basic mechanism of GvHD can be summarized as the attack of immunocompetent donor cells against the tissues of the immunocompromised recipient. [1] GvHD is classified clinically as acute and chronic according to the onset time after BMT. Regardless of clinical findings, it is defined as acute GvHD if followed in the first 100 days after transplantation and chronic GvHD if followed 100 days after transplantation. [2] GvHD is observed in 40% to 60% of patients undergoing BMT concerning recipient and donor-related factors. Mortality occurs in approximately 15% of affected patients. [2]

Cutaneous GvHD usually presents as erythematous maculopapular rashes on the face, ears and palmoplantar region. Follicular erythema is one of the earliest signs of acute cutaneous GvHD. [3, 4] Histopathologic findings of the affected skin are focal or diffuse basal layer epithelial vacuolization in the epidermis (grade I), dyskeratotic keratinocytes adjacent to spongiosis and intraepidermal lymphocytes (grade II), necrotic keratinocytes with eosinophilic cytoplasm, and subepidermal cleavage (grade III), and complete epidermal loss (grade IV).

The suspicion of cutaneous GvHD usually appears with the patient’s clinical findings. [1] Dermatologists undertake an important role in allogeneic BMT patients by assessing the existing rash, suspecting about GvHD and determining the differential diagnosis. [2] Biopsies can be taken from the patients for the confirmation of the diagnosis. [1] Additionally, acute cutaneous GvHD can clinically mimic dermatological disorders, such as drug eruption, viral exanthems, acral erythema, toxic epidermal necrolysis, and radiation dermatitis. Histopathological examination has been playing an important role in the diagnosis and treatment of acute and chronic GvHD in determining the pathophysiology of the disease for many years. According to the National Health Institute consensus THE 2014 Pathology Working Group Report on GvHD, minimal criteria for acute GvHD are: Epidermal/hair follicle outer root sheath/sweat ducts epithelial basal layer±lichenoid inflammation in dermis±lymphocytic satellitosis. The National Health Institute (NIH) recommended final diagnostic categories are: no GvHD, possible GvHD, and likely GvHD. [5] Treatment usually consists of high-dose steroids and in steroid-resistant cases phototherapy. [6]

This study aims to calculate the incidence of cutaneous GvHD in patients who underwent BMT between January 2015 and January 2019 and to discuss the demographic and histomorphological findings of the cutaneous GvHD patients, emphasising the differential diagnosis with the light of the literature.

Methods

The pathology slides of patients who had undergone BMT and diagnosed as cutaneous GvHD in our pathology department were re-evaluated and histomorphological findings were classified; the patient’s clinical and demographic information was obtained from the files. The incidence of cutaneous Graft versus Host Disease was calculated. Ethics committee approval of this study was received from science, social and non-invasive health sciences studies ethical committee on 04.03.2019 (no: 2019/3).

Results

In the last four years, 173 pediatric and 100 adult allogeneic and 181 autologous BMT were performed in our center. We determined cutaneous in 23 patients and gastrointestinal GvHD in 21 patients who underwent allogeneic BMT. The overall rate of GvHD in all patients was 16%; the incidence of cutaneous GvHD was 8.42%. Three (13%) of the patients with cutaneous GvHD had GvHD in the gastrointestinal system. Nine patients (42%) had GvHD in the gastrointestinal tract, while 10 patients (48%) had GvHD in the liver. Two patients had GvHD in both the gastrointestinal tract and liver.

Almost all of the cutaneous GvHD patients (n=22; 95.6%) had acute GvHD; one patient was presenting as chronic GvHD. Eight of the patients were male and 15 were female. Six patients were adult and 17 were pediatric BMT patients.

KIT was performed in eight patients from relatives and in 15 patients from unrelated donors. The patients developed acute cutaneous GvHD at the earliest 12 and at the latest 400 days with an average of 78 days after BMT. The ages of the patients ranged from two to 61, with a mean age of 19 years (Table 1).

Keratinocyte necrosis was the most common epidermal histomorphologic finding in all of the GvHD cases (87%). This was followed by vacuolar degeneration (63%), acanthosis and spongiosis (61%) in basal keratinocytes, respectively. The most common finding in the dermis was pigment incontinence (59%) (Table 2).

Discussion

The incidence of GvHD in patients undergoing allogeneic bone marrow transplantation varies between 40 and 60%, depending on host and donor factors. GvHD is the cause of mortality in 15% of bone marrow transplant patients. [2] In our patients, the incidence of GvHD in the cutaneous and gastrointestinal system was 16%. The relationship be-
between donor gender and donor-recipient is a risk factor for GvHD development. The risk of developing GvHD was higher after BMT was performed with male and unrelated donors. In our study, BMT was performed in eight patients from relatives and in 15 patients from unrelated donors. In acute GvHD, skin involvement is one of the most common symptoms and usually occurs before post-transplant day 100, on average two to four weeks after transplantation. Our patients developed acute cutaneous GvHD at the earliest 12th and at the latest 400th days with an average of 78 days after BMT. The most common localization of cutaneous GvHD in acute form is maculopapular rash starting from the back and trunk and spreading to the palmoplantar region and face. When the skin is the only involved organ, both clinical and histopathological features of acute GvHD may be coincided with drug hypersensitivity reactions, viral exanthem, and lymphocyte healing eruptions, making it difficult to reach a definitive diagnosis. Involvement of certain body regions may be interpreted in favor of acute GvHD in some cases, excluding other differential diagnoses. In a retrospective study conducted by Byun et al., acute GvHD was determined to have more frequent facial involvement than drug hypersensitivity reactions. Additionally, while acute GvHD patients had involvement in the face, palmar and plantar regions, no involvement in these areas was observed in patients diagnosed with drug eruption. In our cases, the most common type of skin rash was maculopapular rash, in accordance with the literature and the most common localization was trunk with 16 cases (70%). This was followed by the palmoplantar region with six cases (29%). In one case, maculopapular rashes were observed in the whole body. Chronic cutaneous GvHD has a wider clinicopathological presentation and the most common type is poikiloderma, lichen planus-like eruptions, lichen sclerosus-like lesions, morphea-like plaques and deep sclerosis. In our chronic GvHD case, morphea-like plaques formed by the combination of hard nodules on the extensor faces of the arms and legs were observed. Histopathological findings included mild fibrosis and melanin incontinence in the papillary dermis and prominent nodular type fibrosis in the deep dermis, together with sparse necrotic keratinocytes in the epidermis (Fig. 1).

### Table 1. Demographic and clinical information of patients with cutaneous GvHD

| Age | Sex | GvHD development time after BMT (days) | Primary disease                        | Is there a kinship between donor and host? |
|-----|-----|---------------------------------------|----------------------------------------|------------------------------------------|
| 3   | M   | 150                                   | Beta thalassemia                       | Yes                                      |
| 4   | M   | 22                                    | Acute lymphoblastic leukemia           | Yes                                      |
| 7   | M   | 400                                   | Acute lymphoblastic leukemia           | Yes                                      |
| 9   | M   | 15                                    | Acute lymphoblastic leukemia           | Yes                                      |
| 17  | M   | 14                                    | Myelodysplastic syndrome               | Yes                                      |
| 17  | F   | 90                                    | Acute lymphoblastic leukemia           | Yes                                      |
| 18  | M   | 17                                    | Chronic myeloid leukemia               | Yes                                      |
| 52  | M   | 30                                    | Myelodysplastic syndrome               | Yes                                      |
| 54  | F   | 25                                    | Acute myeloid leukemia                 | No                                       |
| 2   | M   | 29                                    | Beta thalassemia                       | No                                       |
| 2   | M   | 40                                    | Juvenile myelomonocytic leukemia       | No                                       |
| 4   | M   | 60                                    | Hemophagocytisic lymphohistiocytosis    | No                                       |
| 5   | M   | 40                                    | Acute lymphoblastic leukemia           | No                                       |
| 7   | F   | 26                                    | Acute lymphoblastic leukemia           | No                                       |
| 8   | M   | 110                                   | Acute lymphoblastic leukemia           | No                                       |
| 9   | F   | 270                                   | Aplastic anemia                        | No                                       |
| 10  | M   | 30                                    | Beta thalassemia                       | No                                       |
| 15  | M   | 12                                    | Acute myeloid leukemia                 | No                                       |
| 15  | M   | 14                                    | Aplastic anemia                        | No                                       |
| 29  | F   | 210                                   | Acute lymphoblastic leukemia           | No                                       |
| 31  | F   | 43                                    | Burkitt lymphoma                       | No                                       |
| 61  | M   | 60                                    | Acute myeloid leukemia                 | No                                       |
| 17  | F   | 18                                    | Myelodysplastic syndrome               | No                                       |
### Table 2. Clinical and histomorphological features of cutaneous GvHD patients

| Age | Sex | Clinical differential diagnosis | Clinical findings | Localization | Microscopic epidermal findings | Microscopic dermal findings |
|-----|-----|---------------------------------|-------------------|--------------|--------------------------------|-----------------------------|
| 17  | F   | GvHD? Erythematous maculopapular rash | Trunk             | Atrophy in epidermis | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Atrophy in epidermis | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Keratohyaline globules | |
| 61  | M   | Erythematous maculopapular rash | Trunk             | Atrophy in epidermis | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Keratohyaline globules | |
| 18  | M   | Erythematous maculopapular rash | Trunk             | Atrophy in epidermis | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Keratohyaline globules | |
| 8   | F   | Erythematous maculopapular rash | Trunk             | Atrophy in epidermis | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Fibrosis, edema, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Keratohyaline globules | |
| 39  | M   | Erythematous maculopapular rash | Trunk             | Acanthosis | Fibrosis, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Fibrosis, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Fibrosis, perivascular lymphocytic infiltration |
| 32  | F   | Erythematous maculopapular rash | Trunk             | Atrophy in epidermis | Fibrosis, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Fibrosis, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Fibrosis, perivascular lymphocytic infiltration |
| 54  | F   | Erythematous maculopapular rash | Palmar region     | Acanthosis | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Pigment incontinence, perivascular lymphocytic infiltration |
| 17  | F   | Erythematous maculopapular rash | Palmar region     | Irregular Acanthosis | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Hypergranulosis | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Increased mitotic activity | Pigment incontinence, perivascular lymphocytic infiltration |
| 9   | M   | Erythematous papular rash       | Whole body        | Epidermal thinning | Mild fibrosis, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Necrotic keratinocytes | Mild fibrosis, pigment incontinence, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Basal vacuolar degeneration | Mild fibrosis, pigment incontinence, perivascular lymphocytic infiltration |
| 17  | M   | Erythematous papular rash       | Trunk             | Hyperkeratosis, hypergranulosis, irregular acanthosis, spongiosis, basal vacuolar degeneration, dyskeratotic cells | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Hyperkeratosis, hypergranulosis, | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | irregular acanthosis, spongiosis, | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | basal vacuolar degeneration, | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | dyskeratotic cells | |
| 2   | F   | Erythematous papular rash       | Trunk             | Hyperkeratosis, hypergranulosis, irregular acanthosis, spongiosis, basal vacuolar degeneration, dyskeratotic cells | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | Hyperkeratosis, hypergranulosis, | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | irregular acanthosis, spongiosis, | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | basal vacuolar degeneration, | Pigment incontinence, edema, perivascular lymphocytic infiltration |
|     |     |                                 |                   | dyskeratotic cells | |
| Age | Sex | Clinical differential diagnosis | Clinical findings | Localization | Microscopic epidermal findings | Microscopic dermal findings |
|-----|-----|---------------------------------|-------------------|-------------|--------------------------------|-----------------------------|
| 4   | M   | GvHD? Drug eruption?            | Violaceous plaques| Palmoplantar region | Hyperkeratosis, hypergranulosis, irregular acanthosis, spongiosis, basal vacuolar degeneration, dyskeratotic cells | Pigment incontinence, edema, perivascular lymphocytic infiltration |
| 8   | M   | GvHD                           | Violaceous maculopapular rash | Plantar region | Hyperkeratosis, achanthosis, necrotic keratinocytes | Mild fibrosis, sparse pigment incontinence, perivascular lymphocytic infiltration |
| 2   | M   | GvHD                           | Violaceous maculopapular rash | Plantar region | Hyperkeratosis, achanthosis, necrotic keratinocytes | Mild fibrosis, sparse pigment incontinence, perivascular lymphocytic infiltration |
| 7   | M   | GvHD                           | Violaceous maculopapular rash | Trunk         | Hyperkeratosis, achanthosis, Necrotic keratinocytes | Mild fibrosis, sparse pigment incontinence, perivascular lymphocytic infiltration |
| 9   | F   | GvHD                           | Violaceous maculopapular rash | Trunk         | Hyperkeratosis, necrotic keratinocytes | Mild fibrosis, sparse pigment incontinence, perivascular lymphocytic infiltration |
| 3   | M   | GvHD                           | Erythematous maculopapular rash | Trunk         | Acanthosis Spongiosis Basal vacuolar degeneration Necrotic keratinocytes | Edema ve perivascular lymphocytic infiltration |
| 29  | F   | GvHD? Drug eruption? Cutaneous metastasis? | Erythematous maculopapular rash, tending to merge | Palmar region | Hyperkeratosis, achanthosis, spongiosis, dyskeratotic cells, Basal vacuolar degeneration | Pigment incontinence, perivascular lymphocytic infiltration |
| 11  | M   | GvHD?                          | Erythematous maculopapular rash | Trunk         | Normal findings | Perivascular lymphoplasmacytic infiltration |
| 16  | M   | GvHD? Sezary syndrome?         | Papular rash        | Trunk         | Acanthosis Spongiosis Basal vacuolar degeneration Sparse necrotic keratinocytes | Pigment incontinence, congestion, fibrosis |
| 15  | M   | Vasculitis? GvHD?              | Violaceous papules and nodules hard on palpation | Trunk and face | Irregular Acanthosis Basal vacuolar degeneration Necrotic keratinocytes | Erythrocyte extravasation, perivascular lymphoplasmacytic infiltration |
dyskeratotic keratinocytes. Mild mononuclear superficial perivascular infiltrate are other findings. In later stages, epithelial damage occurs on the rete tips and hair follicles. These findings occur when T lymphocytes attack and destroy activated donor lymphocytes.[1] In our cases, the most common epidermal histomorphologic findings were keratinocyte necrosis (87%) and vacuolar degeneration in basal keratinocytes (63%), consistent with the literature (Fig. 2). These findings were followed by acanthosis and spongiosis (61%). The most common dermal finding was pigment incontinence (59%) (Fig. 3).

Acute GvHD is histopathologically divided into four grades. Although these degrees are not clinically important, it is important for pathologists to be familiar with all forms of GvHD concerning lesions that may be involved in the differential diagnosis (Table 3).[8] In our acute cutaneous GvHD cases, one patient had grade 1 and two patients had grade 4 GvHD, while the remaining twenty-two patients had grade 2 GvHD.

In severe drug reactions, such as erythema multiforme and toxic epidermal necrolysis, vacuolization of the basal keratinocytes and necrotic keratinocytes may also be encountered, as seen in acute cutaneous GvHD.[12] Formerly, it was stated that monitoring a mixed inflammatory cell infiltration in the dermis, including eosinophils, might sometimes help differentiate these entities from GvHD.[13] However, according to the recent national institutes of health consensus, the presence of tissue eosinophils in a skin biopsy should not be considered as evidence for drug hypersensitivity since they often occur in GvHD.[5]

In a study by Hausermann et al., the authors determined that the lymphocyte/macrophage ratio could help differentiate between toxic epidermal necrolysis and cutaneous GvHD. In cutaneous GvHD, since immunosuppressive therapy is used after the transplantation, the predominant cells are macrophages. If the immunosuppressive regimen fails, there is a predominance of T lymphocytes over macrophages.[14] Similarly, Nishiwaki et al. noted that many cells in the dermal inflammatory infiltrate in untreated acute GvHD were actually CD163+ macrophages rather than T-cells.[8]

It should also be kept in mind that drug reactions and GvHD may coexist. Furthermore, reactions due to certain chemotherapeutic agents (e.g., Busulphan) may mimic GvHD histopathologically without GvHD in the patient’s clinical picture.[15] In addition, histopathological findings of GvHD can coincide with diseases, such as viral exanthems, staphylococcal scalded skin syndrome. Therefore, in the differential diagnosis of GvHD, clinicopathological correlation is important as in all other dermatopatholog-

Figure 1. (a, b) Pigment incontinence in papillary dermis (black arrow); prominent, nodular type fibrosis in deep dermis (red arrows) (H&E, 100X, 200X).

Figure 2. Basal layer vacuolar degeneration (red arrows) and numerous necrotic keratinocytes (green arrows) in the epidermis (H&E, 200X).

Figure 3. Many melanophages in the dermis, compatible with melan incontinence (H&E, 200X).
ical diseases. Clinician’s approach to the patient, preliminary diagnoses, drugs used by the patient may guide the pathologist in the differential diagnosis. In one of our cases, atrophy in the epidermis, basal vacuolar degeneration, necrotic keratinocytes, keratohyalin globules, as well as severely atypical keratinocytes were observed in the epidermis (Fig. 4). We found that our patient was on Busulphan. Since we had classical histopathological GvHD findings, as well as severe keratinocyte dysplasia, due to the use of Busulphan, we questioned whether the patient had clinical signs of GvHD and reached the correct diagnosis with clinicopathological correlation.

**Conclusion**

GvHD is one of the most important causes of morbidity and mortality observed in allogeneic BMT recipients. The diagnosis can be made with clinical suspicion and histopathological verification. To reach the diagnosis, the recognition of the early and late histopathological findings and the differential diagnosis by the pathologists together with a clinicopathological correlation is the gold standard.

**Table 3. Histopathological grading of acute GvHD**

| Grade | Description |
|-------|-------------|
| I.    | Vacuolar change at dermoepidermal junction |
| II.   | Changes in grade I, dyskeratotic cells, lymphocytic infiltration in dermis. |
| III.  | Changes in grade II, merging of the basal vacuoles and microvesicle formation |
| IV.   | Severe necrosis and denudation of epidermis, dermoepidermal splitting |

**Figure 4.** Severe keratinocyte atypia (black arrows), together with basal vacuolar degeneration (red arrows) and necrotic keratinocytes (red arrowheads) in epidermis and melanin incontinence in the dermis (green arrows) (H&E, 400 X).

**Disclosures**

**Ethics Committee Approval:** Ethics committee approval of this study was received from science, social and non-invasive health sciences studies ethical committee on 04.03.2019 (no: 2019/3).

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** No conflict of interest is declared by the authors.

**Financial Disclosure:** The authors declare that this study received no financial support.

**Authorship Contributions:** Concept – U.P.; Design – U.P., D.S.; Supervision – D.S.; Materials – U.P.; Data collection &/or processing – U.P.; Analysis and/or interpretation – U.P., D.S.; Literature search – U.P.; Writing – U.P.; Critical review – D.S.

**References**

1. Villarreal CD, Alanis JC, Pérez JC, Candiani JO. Cutaneous graft-versus-host disease after hematopoietic stem cell transplant - a review. An Bras Dermatol 2016;91:336–43.
2. Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol 2018;19:33–50.
3. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–56.
4. Friedman KJ, LeBoit PE, Farmer ER. Acute follicular graft-vs-host reaction. A distinct clinicopathologic presentation. Arch Dermatol 1988;124:688–91.
5. Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015;21:589–603.
6. Yanamandra U, Nahar Saikia U, Prakash G, Khadwal A, Malhotra P, Varma S. Skin GVHD mimicking betadine rash in a post allogeneic transplant patient. Indian J Hematol Blood Transfus 2017;33:427–30.
7. Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, et al. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Adv 2018;2:1022–31.
8. Nishiwaki S, Terakura S, Ito M, Goto T, Seto A, Watanabe K, et al. Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood 2009;114:3113–6.
9. Santos E Sousa P, Bennett CL, Chakraverty R. Unraveling the mechanisms of cutaneous graft-versus-host disease. Front Immunol 2018;9:963.
10. Byun HJ, Yang JI, Kim BK, Cho KH. Clinical differentiation of acute cutaneous graft-versus-host disease from drug hypersensitivity
reactions. J Am Acad Dermatol 2011;65:726–32.
11. Prieto-Torres L, Boggio F, Gruber-Wackernagel A, Cerroni L. Nodular sclerodermatous chronic cutaneous graft-versus-host disease (GvHD): a new clinicopathological variant of cutaneous sclerodermatous GvHD resembling nodular/keloidal scleroderma. Am J Dermatopathol 2017;39:910–3.
12. Gökdemir G, Kivanç-Altunay İ, Göksu F, Köşlü A. Clinical course of bullous erythema multiforme receiving high-dose corticosteroid treatment. Med Bull Sisli Etfal Hosp 1999;33:44–8.
13. Zhang Y, Ruiz P. Solid organ transplant-associated acute graft-versus-host disease. Arch Pathol Lab Med 2010;134:1220–4.
14. Piérard GE, Hermanns-Lê T, Paquet P, Rousseau AF, Delvenne P, Piérard-Franchimont C. Toxic epidermal necrolysis and graft-versus-host reaction: revisiting a puzzling similarity. ISRN Dermatol 2013;2013:651590.
15. Li N, Guthrie KA, Storer BE, Martin PJ, Sale GE, Argenyi ZB, et al. Keratinocyte dysplasia in hematopoietic stem cell transplantation recipients in the day-28-to-84 posttransplantation period. Biol Blood Marrow Transplant 2012;18:1281–6.